IQP-0528 | SJ-3991 | CAS#301297-45-0 | Non-Nucleoside Reverse Transcriptase Inhibitor

MedKoo Cat#: 527518 | Name: IQP-0528

Description:

WARNING: This product is for research use only, not for human or veterinary use.

IQP-0528, also known as SJ-3991, is a non-nucleoside reverse transcriptase inhibitor potentially for the treatment of HIV infection. IQP-0528 works by blocking virus entry and has shown antiviral activity as microbicide gels.

Chemical Structure

IQP-0528

CAS#301297-45-0

Theoretical Analysis

MedKoo Cat#: 527518

Name: IQP-0528

CAS#: 301297-45-0

Chemical Formula: C20H24N2O3

Exact Mass: 340.1787

Molecular Weight: 340.42

Elemental Analysis: C, 70.57; H, 7.11; N, 8.23; O, 14.10

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

IQP-0528; IQP 0528; IQP0528; SJ-3991; SJ3991; SJ3991

IUPAC/Chemical Name

1-(cyclopropylmethyl)-6-(3,5-dimethylbenzoyl)-5-isopropylpyrimidine-2,4(1H,3H)-dione

InChi Key

UCOAKFIVSAVHLC-UHFFFAOYSA-N

InChi Code

InChI=1S/C20H24N2O3/c1-11(2)16-17(18(23)15-8-12(3)7-13(4)9-15)22(10-14-5-6-14)20(25)21-19(16)24/h7-9,11,14H,5-6,10H2,1-4H3,(H,21,24,25)

SMILES Code

O=C1NC(C(C(C)C)=C(C(C2=CC(C)=CC(C)=C2)=O)N1CC3CC3)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 340.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Pereira LE, Mesquita PM, Ham A, Singletary T, Deyounks F, Martin A, McNicholl J, Buckheit KW, Buckheit RW Jr, Smith JM. Pharmacokinetic and Pharmacodynamic Evaluation following Vaginal Application of IQB3002, a Dual-Chamber Microbicide Gel Containing the Nonnucleoside Reverse Transcriptase Inhibitor IQP-0528 in Rhesus Macaques. Antimicrob Agents Chemother. 2015 Dec 14;60(3):1393-400. doi: 10.1128/AAC.02201-15. PubMed PMID: 26666935; PubMed Central PMCID: PMC4775942. 2: Srinivasan P, Zhang J, Martin A, Kelley K, McNicholl JM, Buckheit RW Jr, Smith JM, Ham AS. Safety and Pharmacokinetics of Quick-Dissolving Polymeric Vaginal Films Delivering the Antiretroviral IQP-0528 for Preexposure Prophylaxis. Antimicrob Agents Chemother. 2016 Jun 20;60(7):4140-50. doi: 10.1128/AAC.00082-16. PubMed PMID: 27139475; PubMed Central PMCID: PMC4914618. 3: Dezzutti CS, Shetler C, Mahalingam A, Ugaonkar SR, Gwozdz G, Buckheit KW, Buckheit RW Jr. Safety and efficacy of tenofovir/IQP-0528 combination gels - a dual compartment microbicide for HIV-1 prevention. Antiviral Res. 2012 Nov;96(2):221-5. doi: 10.1016/j.antiviral.2012.08.004. PubMed PMID: 22940075; PubMed Central PMCID: PMC3501576. 4: Ham AS, Rohan LC, Boczar A, Yang L, W Buckheit K, Buckheit RW Jr. Vaginal film drug delivery of the pyrimidinedione IQP-0528 for the prevention of HIV infection. Pharm Res. 2012 Jul;29(7):1897-907. doi: 10.1007/s11095-012-0715-7. PubMed PMID: 22392331; PubMed Central PMCID: PMC4405790. 5: Ham AS, Ugaonkar SR, Shi L, Buckheit KW, Lakougna H, Nagaraja U, Gwozdz G, Goldman L, Kiser PF, Buckheit RW Jr. Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection. J Pharm Sci. 2012 Apr;101(4):1423-35. doi: 10.1002/jps.23026. PubMed PMID: 22227864. 6: Mahalingam A, Simmons AP, Ugaonkar SR, Watson KM, Dezzutti CS, Rohan LC, Buckheit RW Jr, Kiser PF. Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother. 2011 Apr;55(4):1650-60. doi: 10.1128/AAC.01368-10. PubMed PMID: 21245437; PubMed Central PMCID: PMC3067148. 7: Ugaonkar SR, Clark JT, English LB, Johnson TJ, Buckheit KW, Bahde RJ, Appella DH, Buckheit RW Jr, Kiser PF. An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission. J Pharm Sci. 2015 Oct;104(10):3426-39. doi: 10.1002/jps.24551. PubMed PMID: 26149293; PubMed Central PMCID: PMC4822498. 8: Ham AS, Nugent ST, Peters JJ, Katz DF, Shelter CM, Dezzutti CS, Boczar AD, Buckheit KW, Buckheit RW Jr. The rational design and development of a dual chamber vaginal/rectal microbicide gel formulation for HIV prevention. Antiviral Res. 2015 Aug;120:153-64. doi: 10.1016/j.antiviral.2015.06.010. PubMed PMID: 26093158; PubMed Central PMCID: PMC4492852. 9: Rastogi R, Teller RS, Mesquita PM, Herold BC, Kiser PF. Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa. Antiviral Res. 2013 Oct;100(1):255-8. doi: 10.1016/j.antiviral.2013.08.007. PubMed PMID: 23973812; PubMed Central PMCID: PMC3924427. 10: Mesquita PM, Srinivasan P, Johnson TJ, Rastogi R, Evans-Strickfaden T, Kay MS, Buckheit KW, Buckheit RW Jr, Smith JM, Kiser PF, Herold BC. Novel preclinical models of topical PrEP pharmacodynamics provide rationale for combination of drugs with complementary properties. Retrovirology. 2013 Oct 24;10:113. doi: 10.1186/1742-4690-10-113. PubMed PMID: 24156604; PubMed Central PMCID: PMC3827994. 11: Chuchuen O, Henderson MH, Sykes C, Kim MS, Kashuba AD, Katz DF. Quantitative analysis of microbicide concentrations in fluids, gels and tissues using confocal Raman spectroscopy. PLoS One. 2013 Dec 30;8(12):e85124. doi: 10.1371/journal.pone.0085124. PubMed PMID: 24386455; PubMed Central PMCID: PMC3875564. 12: Johnson TJ, Srinivasan P, Albright TH, Watson-Buckheit K, Rabe L, Martin A, Pau CP, Hendry RM, Otten R, McNicholl J, Buckheit R Jr, Smith J, Kiser PF. Safe and sustained vaginal delivery of pyrimidinedione HIV-1 inhibitors from polyurethane intravaginal rings. Antimicrob Agents Chemother. 2012 Mar;56(3):1291-9. doi: 10.1128/AAC.05721-11. PubMed PMID: 22155820; PubMed Central PMCID: PMC3294899.